Рівень чинника некрозу пухлин альфа і його кореляційні взаємозв'язки у хворих на цукровий діабет 2-го типу з неалкогольною жировою хворобою печінки
DOI:
https://doi.org/10.24026/1818-1384.1(46).2014.75324Ключові слова:
type 2 diabetes, nonalcoholic fatty liver disease, TNF-α, insulin resistance, obesityАнотація
The article describes changes in serum levels of TNF-α and defines its associative relationships with anthropometric parameters and metabolic profile in patients with type 2 diabetes based on the presence NAFLD. According to our results the concentration of TNF-α in serum was statistically significantly higher in patients with NAFLD compared with the control group. In patients with NAFLD and normal transaminase levels TNF-α was higher on 45.5% (p=0,01) and 137,7% respectively (p<0,001) in patients with elevated transaminases compared to control group, in which the average cytokine serum concentration was 33,45±1,91 pg/ml. In all groups independent determinants associated with TNF-α in regression analysis were obesity and IR. In patients with NAFLD and normal range of liver enzymes compared to the control group showed an association with HDL-C and TG levels, and in the group with elevated transaminases also with ALT and AST.
Посилання
Angulo P. Nonalcoholic fatty liver disease // New England Journal of Medicine. – 2002. – Vol. 346. – P. 1221-1231. https://doi.org/10.1056/nejmra011775
Боднар П.М., Михальчишин Г.П., Кобиляк Н.М. Неалкогольна жирова хвороба печінки у хворих на цукровий діабет типу 2: патогенез, діагностика та лікування (лекція) // Ендокринологія. – 2012. – Т.17, No 1. – С. 94-101.
Драпкина О.М., Смирин В.И., Ивашкин В.Т. Патогенез, лечение и эпидемиология НАЖБП – что нового? Эпидемиология в России // РМЖ. – 2011. – No 28. – С. 1717-1722.
Blachier M., Leleu H., Peck-Radosavljevic M. The burden of liver disease in Europe: a review of available epidemiological data // J. Hepatol. – 2013. – Vol. 58, No 3. – P. 593-608. https://doi.org/10.1016/j.jhep.2012.12.005
Бабак О.Я., Колесникова Е.В. Патогенетические механизмы формирования неалкогольной жировой болезни печени: фокус на клиническое применение адеметионина // Сучасна гастроентерологія. – 2011. – No 3 (59). – С. 56-63.
Взаємозв’язок неалкогольної жирової хвороби печінки та розвитку судинних ускладнень у хворих на цукровий діабет 2 типу, терапевтичні підходи (огляд літератури) / Кравчун Н.О., Полторак В.В., Земляніцина О.В. та ін. // Проблеми ендокринної патології. – 2011. – No 1. – С. 67-75.
Бобронникова Л.Р., Журавлева А.К. Факторы прогрессирования метаболических нарушений в печени у пациентов с сочетанным течением неалкогольной жировой болезни печени и сахарного диабета 2 типа // Ендокринологія. – 2013. – Т.18, No 1. – С. 54-58.
Єлізарова Т.О., Кузнєцова Л.В. Концентрація прозапальних цитокінів у сироватці крові хворих на неалкоголий стеатогепатит // Імунологія та алергологія: наука і практика. – 2010. – No 3-4. – С. 49-53.
Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. // N. Engl. J. Med. – 2000. – Vol. 343. – P. 1467-1476. https://doi.org/10.1056/nejm200011163432007
Tartaglia L.A., Goeddel D.V. Two TNF receptors. // Immunol. Today. – 1992. – Vol. 13. – P. 151-153. https://doi.org/10.1016/0167-5699(92)90116-o
Uysal K.T., Wiesbrock S.M., Marino M.W. et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function // Nature. – 1997. – Vol. 389. – P. 610-614. https://doi.org/10.1038/39335
Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association // Hepatology. – 2012. – Vol. 55, No 6. – P. 2005-2023. https://doi.org/10.1002/hep.25762
Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance // Science. – 1993. – Vol. 259. – P. 87-91. https://doi.org/10.1126/science.7678183
Tilg H., Hotamisligil G.S. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance // Gastroenterology. – 2006. – Vol. 131. – P. 934-945. https://doi.org/10.1053/j.gastro.2006.05.054
Uysal K.T., Wiesbrock S.M., Marino M.W. et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function // Nature. – 1997. – Vol. 389. – P. 610-614.
Lucero D., Zago V., Lopez G.I. et al. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome // Clin. Chim. Acta. – 2011. – Vol. 412. – P. 143-147. https://doi.org/10.1016/j.cca.2010.09.025
Bruun J.M., Verdich C., Toubro S. et al. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men // Eur. J. Endocrinol. – 2003. – Vol. 148. – P. 535-542. https://doi.org/10.1530/eje.0.1480535
Ofei F., Hurel S., Newkirk J. et al. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. // Diabetes. – 1996. – Vol. 45. – P. 881-885. https://doi.org/10.2337/diabetes.45.7.881
Bernstein L.E., Berry J., Kim S. et al. Effects of etanercept in patients with the metabolic syndrome // Arch. Intern. Med. – 2006. – Vol. 166. – P. 902-908. https://doi.org/10.1001/archinte.166.8.902
Hirosumi J., Tuncman G., Chang L. et. al. A central role for JNK in obesity and insulin resistance // Nature. – 2002. – Vol. 21, No 420. – P. 333-336. https://doi.org/10.1038/nature01137
Yuan M., Konstantopoulos N., Lee J. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk-β // Science. – 2001. – Vol. 293. – P. 1673-1677. https://doi.org/10.1126/science.1061620
Shoelson S.E., Lee J., Yuan M. Inflammation and the IKK-β/I-kB/NF-kB axis in obesity- and diet-induced insulin resistance // Int. J. Obes. Relat. Metab. Disord. – 2003. – Vol. 27. – P. 49-52. https://doi.org/10.1038/sj.ijo.0802501
Gao Z., Hwang D., Bataille F. et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex // J. Biol. Chem. – 2002. – Vol. 277. – P. 48115-48121. https://doi.org/10.1074/jbc.m209459200
Cai D., Yuan M., Frantz D.F. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK- β and NF-κB // Nat. Med. – 2005. – Vol. 11. – P. 183-190. https://doi.org/10.1038/nm1166
Hundal R.S., Petersen K.F., Mayerson A.B. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes // J. Clin. Invest. – 2002. – Vol. 109. – P. 1321-1326. https://doi.org/10.1172/jci14955
Dandona P., Weinstock R., Thusu K. et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss // J. Clin Endocrinol. Metab. – 1998. – Vol. 83. – P. 2907-2910. https://doi.org/10.1210/jcem.83.8.5026
Kern P.A., Saghizadeh M., Ong J.M. et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase // J. Clin. Invest. – 1995. – Vol. 95. – P. 2111-2119. https://doi.org/10.1172/jci117899
Pinto L.F., Compri C.M., Fornari J.V. et al. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice // Liver Int. – 2010. – Vol. 30. – P. 603-610. https://doi.org/10.1111/j.1478-3231.2009.02200.x
Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K. et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and cholinedeficient diet // Inflammation. – 2008. – Vol. 31. – P. 91-98. https://doi.org/10.1007/s10753-007-9053-z
Lesmana C.R., Hasan I., Budihusodo U. et al. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis // J. Dig. Dis. – 2009. – Vol. 10. – P. 201-206. https://doi.org/10.1111/j.1751-2980.2009.00386.x
Crespo J., Cayon A., Fernandez-Gil P. et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients // Hepatology. – 2001. – Vol. 34. – P. 1158-1163. https://doi.org/10.1053/jhep.2001.29628
Lee Y.M., Sutedja D.S., Wai C.T. et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH) // Hepatol. Int. – 2008. – No 2. – P. 196-201. https://doi.org/10.1007/s12072-008-9058-1
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2017 Клінічна ендокринологія та ендокринна хірургія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
